Type of security: Stock
Sector: Health Care
Industry: Biotechnology: Biological Products (No Diagnostic Substances)
The data is delayed by 15 minutes.
BIIB is in the long-term up 180% above S&P in 20 years.
Description: Biogen Idec Inc. discovers, develops, manufactures, and markets therapies for the treatment of multiple sclerosis (MS), neurodegenerative diseases, hemophilia, and autoimmune disorders in the United States and internationally. It provides AVONEX to treat relapsing MS; TYSABRI to treat relapsing forms of MS and Crohn?s disease; RITUXAN for treating relapsed or refractory, follicular, CD20-positive, and B-cell Non-Hodgkin?s lymphoma (NHL); FUMADERM to treat severe plaque psoriasis in adult patients; FAMPYRA, an oral compound for the improvement of walking in adult patients with MS; TECFIDERA for the treatment of MS; and GAZYVA, an injection for intravenous infusion that treats an untreated chronic lymphocytic leukemia. The company?s products that completed Phase III clinical trials comprise ELOCTATE and ALPROLIX, an inherited disorder that inhibits blood coagulations; and Peginterferon beta-1a to prolong the effects and reduce the dosing frequency of interferon beta-1a. Its products under Phase III clinical tri
See how to gain 20% in 14 sec with TrendsInvesting
|Shares Outstanding||EPS||17.73||EPS Growth - 4 Quarters||EPS Growth - Q/Q|
|EPS Growth - Y/Y||Sales Growth - 4 Quarters||3.19%||Sales Growth - Q/Q||1.44%||P/E||14.2|
|P/E To EPS Growth||P/S||P/BV||Price/Cash Per Share|
|Price/Free Cash Flow||ROA||20.83%||ROE||27.76%||ROI||24.82%|
|Current Ratio||2.2||Quick Ratio||1.86||Long Term Debt/Equity||0.19||Debt Ratio||0.2|
|Gross Margin||88.36%||Operating Margin||45.28%||Net Profit Margin||33.89%||Dividend Payout Ratio|
|Cash From Financing Activities||77.22 M||Cash From Investing Activities||-1.76 B||Cash From Operating Activities||1.78 B||Gross Profit||2.31 B|
|Net Profit||927.28 M||Operating Profit||1.23 B||Total Assets||16.76 B||Total Current Assets||5.62 B|
|Total Current Liabilities||2.56 B||Total Debt||579.47 M||Total Liabilities||4.19 B||Total Revenue||2.59 B|
|High 52 week||367.91||Low 52 week||257.52||Last close||358.11||Last change||-0.11%|
|RSI||84.19||Average true range||11.63||Beta||1.03||Volume||1.07 M|
|Simple moving average 20 days||10.98%||Simple moving average 50 days||17.89%||Simple moving average 200 days||16.97%|
|Performance Week||3.01%||Performance Month||22.62%||Performance Quart||34.62%||Performance Half||3.97%|
|Performance Year||27.01%||Performance Year-to-date||12.41%||Volatility daily||3.95%||Volatility weekly||8.83%|
|Volatility monthly||18.1%||Volatility yearly||62.72%||Relative Volume||178.46%||Average Volume||1.85 M|
|New High||New Low|
2019-06-14 12:03:32 | Why Alzheimer's Treatment Hopes Endure Despite High-Profile Drug Failures
2019-06-13 17:50:09 | Biogen BIIB Gains But Lags Market: What You Should Know
2019-06-13 16:12:00 | Amgen, Biogen, Gilead and Novo Nordisk have ‘very high’ capacity for M&A, says Moody’s
2019-06-12 12:49:48 | Biogen Inc. NASDAQ:BIIB Insiders Increased Their Holdings
2019-06-12 09:27:01 | Biotech Stock Roundup: Celgene Submits MS Drug to FDA, INSY & CBAY Crash
2019-06-11 11:26:38 | Zynerba Stock Soars on Cannabidiol Patent for Autism Spectrum Disorder
2019-06-10 16:40:26 | Is Biogen Inc. BIIB A Good Stock To Buy?
2019-06-10 08:08:05 | See what the IHS Markit Score report has to say about Biogen Inc.
2019-06-07 17:50:09 | Biogen BIIB Outpaces Stock Market Gains: What You Should Know
2019-06-07 17:00:09 | Celgene's Filing for Ozanimod Accepted for Review in US/EU
2019-06-07 05:41:57 | Biogen Completes Acquisition of Nightstar Therapeutics for Approximately $800 Million
2019-06-06 16:19:44 | Will This Downbeat Biotech Regain Investor Trust With ALS Drugs?
2019-06-06 10:38:00 | Biogen Stock Is Slipping Because Investors Don’t Buy Its News on Lou Gehrig’s Disease
2019-05-31 09:07:01 | Biogen Reports Interim Phase III Data on Diroximel Fumarate
2019-05-31 09:01:13 | What Are Gilead Sciences’ Key Growth Drivers in 2019?
2019-05-31 08:11:12 | Roche RHHBY Up 6.3% YTD on Strong Demand for New Drugs
2019-05-31 07:32:27 | How Is Biogen’s Tecfidera Positioned in 2019?
2019-05-31 07:32:18 | How Is Gilead Sciences Revamping Its NASH Strategy in 2019?
2019-05-30 18:00:12 | How Is Biogen’s Alzheimers’ Disease Pipeline Positioned in 2019?
2019-05-30 11:02:03 | PDL BioPharma's Royalties Help, Heavy Partner Reliance Hurts
2019-05-30 07:15:00 | The Case for a Biogen Acquisition — and 3 Potential Targets
2019-05-29 17:50:09 | Biogen BIIB Dips More Than Broader Markets: What You Should Know
2019-05-29 08:59:12 | Celgene's Revlimid-Rituximab Combo Gets FDA Nod for Lymphoma
2019-05-28 07:00:00 | Primecap’s Golden Lineup: Its Six Funds Come in Pairs
2019-05-27 06:48:10 | Roche Gets FDA Nod for Expansion of Cobas 6800/8800 Systems
2019-05-24 19:39:48 | For Anderson family, an early bet on SMA gene therapy
2019-05-24 19:39:48 | Novartis $2 million gene therapy for rare disorder is world's most expensive drug
2019-05-24 17:05:29 | Novartis Gene Therapy Crosses The $2 Million Mark — Will Others Follow?
2019-05-24 13:30:35 | Biogen loses edge on blockbuster rare disease market with Novartis' FDA approval
2019-05-24 10:55:55 | Biogen Stock One of the Best to Own Next Week
2019-05-24 09:31:01 | Biogen BIIB Down 0.3% Since Last Earnings Report: Can It Rebound?
2019-05-23 17:27:24 | Preclinical biotech Stoke Therapeutics plans $86M IPO
2019-05-23 15:53:07 | Earnings Preview: Veeva VEEV, Palo Alto Networks PANW, Workday WDAY
2019-05-23 09:06:00 | Wedbush Securities Senior Vice President of Equity Research Laura Chico, Ph.D. Initiates Coverage on Six Stocks in the Healthcare and BioTech Space - ACER, ACOR, ALNX, BIIB, DOVA and SAGE
2019-05-23 07:10:24 | The top-performing hedge funds are buying GE, Facebook, Biogen and these other stocks
2019-05-22 16:30:08 | 3 Tech Stocks for Growth Investors to Buy Right Now
2019-05-22 14:43:06 | Top Research Reports for Chubb, Las Vegas Sands & Biogen
2019-05-22 11:34:03 | Biotech Stock Roundup: Label Expansion for CELG's Drugs, Setback for IMGN
2019-05-22 11:08:27 | Dalio’s Bridgewater: Major Stocks Positions and New Buys in Q1
2019-05-21 17:56:00 | The Best and Worst Big Biotech Stocks, According to One Analyst
2019-05-21 16:55:19 | We don't yet have the technology to cure Alzheimer's, health-care investor says
2019-05-21 15:00:33 | Apple, Biogen, Diamondback Energy and More: Why These Stocks Are Trending
2019-05-20 16:30:57 | Biogen Urges Shareholders To Reject Low-Ball Mini-Tender Offer
2019-05-20 07:40:00 | Biogen urges shareholders to reject 'below-market' mini-tender offer from TRC Capital
2019-05-17 17:17:09 | Celgene Gets EC Nod for Label Expansion of Revlimid, Imnovid
2019-05-16 14:54:49 | Wayfair cracks Fortune 500 list, joins 15 other Mass. companies